Scarica l'app Stockscreener
192.12
3.93%
-8.05
Precedente Chiudi:
$200.17
Aprire:
$197.52
Volume 24 ore:
446.53K
Relative Volume:
0.37
Capitalizzazione di mercato:
$27.40B
Reddito:
$2.31B
Utile/perdita netta:
$-208.16M
Rapporto P/E:
-125.03
EPS:
-1.5366
Flusso di cassa netto:
$76.11M
1 W Prestazione:
-7.45%
1M Prestazione:
+5.29%
6M Prestazione:
-0.26%
1 anno Prestazione:
+24.16%
Intervallo 1D:
$191.89
$199.81
Intervallo di 1 settimana:
$192.10
$207.79
Portata 52W:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
191.89 | 28.58B | 2.31B | -208.16M | 76.11M | -1.5366 |
TMO
Thermo Fisher Scientific Inc
|
465.52 | 174.74B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.68 | 126.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
548.63 | 45.14B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
111.02 | 32.46B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
290.49 | 29.52B | 3.17B | 642.63M | 516.49M | 10.77 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | William Blair | Outperform |
| 2026-01-07 | Iniziato | Citigroup | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-27 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
A Look At Natera (NTRA) Valuation After Prospera Transplant Data At ISHLT Annual Meeting - simplywall.st
Should You Be Bullish on Natera (NTRA)? - Insider Monkey
Natera (NASDAQ: NTRA) director awarded fully vested RSUs in lieu of cash - Stock Titan
Natera (NTRA) director Roelof Botha receives RSU awards and reports 1.15M indirect shares - Stock Titan
Natera awarded 30% ongoing royalty in MRD patent litigation - msn.com
Natera, Inc. (NTRA) Stock Analysis: Unpacking a 26.63% Potential Upside in the Booming Diagnostics Sector - DirectorsTalk Interviews
Natera's Signatera data suggests select breast cancer patients could skip surgery - MSN
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
M&T Bank Corp Increases Stock Position in Natera, Inc. $NTRA - MarketBeat
Unveiling Natera (NTRA) Q4 outlook: Wall Street estimates for key metrics - MSN
What Natera (NTRA)'s New Prospera Transplant Data Momentum Means For Shareholders - simplywall.st
Is It Too Late To Consider Natera (NTRA) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Teacher Retirement System of Texas Has $15.06 Million Holdings in Natera, Inc. $NTRA - MarketBeat
Natera Urges High Court To Reject CareDx's False Ad Petition - Law360
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile
Universal Beteiligungs und Servicegesellschaft mbH Has $30.18 Million Stake in Natera, Inc. $NTRA - MarketBeat
NTRA Stock Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera, Inc. ($NTRA) CEO and President 2025 Pay Revealed - Quiver Quantitative
[ARS] Natera, Inc. SEC Filing - Stock Titan
Natera (NASDAQ: NTRA) details 2026 meeting agenda, pay votes and equity plan expansion - Stock Titan
Is It Too Late To Consider Natera (NTRA) After Its Recent Share Price Surge? - simplywall.st
Why (NTRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Natera (NTRA) Showcases Promising Evidence for Prospera Test at ISHLT Meeting - GuruFocus
17 transplant studies show Prospera flags earlier heart, lung warning signs - Stock Titan
Natera co-founder Sheena Jonathan sells $299,440 in shares By Investing.com - Investing.com India
Natera co-founder Sheena Jonathan sells $299,440 in shares - Investing.com
Natera (NTRA) co-founder’s family trusts sell 1,500 shares under 10b5-1 plan - Stock Titan
Judge hands Natera 30% ongoing royalty in MRD patent battle - MSN
Natera positioned to capture growing $20 billion MRD opportunity: analyst - MSN
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA) - Yahoo Finance
3 Reasons We’re Fans of Natera (NTRA) - Yahoo Finance
Natera, Inc. $NTRA Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Natera, Inc. (NTRA) Stock Analysis: A 23.78% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Court orders 30% ongoing royalty for Natera in patent dispute - MSN
KBC Group NV Buys 14,346 Shares of Natera, Inc. $NTRA - MarketBeat
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know - Yahoo Finance
Cwm LLC Has $19 Million Holdings in Natera, Inc. $NTRA - MarketBeat
Natera, UFP Technologies, Mettler-Toledo, and Viatris shares are soaring, what you need to know - MSN
Chicago Capital LLC Purchases 12,805 Shares of Natera, Inc. $NTRA - MarketBeat
Natera, Inc. (NASDAQ:NTRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Natera (NASDAQ:NTRA) Rating Increased to Buy at Wall Street Zen - MarketBeat
Class Action Certification and CLARITY MRD Data Might Change The Case For Investing In Natera (NTRA) - simplywall.st
NTRA Technical Analysis | Trend, Signals & Chart Patterns | NATERA INC (NASDAQ:NTRA) - ChartMill
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Tops Q4 Earnings and Revenue Estimates - Eastern Progress
Is It Time To Reassess Natera (NTRA) After Its Mixed Share Price Performance? - simplywall.st
Barclays Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $280 - Moomoo
Natera, Inc. (NASDAQ:NTRA) Short Interest Up 47.2% in March - MarketBeat
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Natera Inc Azioni (NTRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Apr 06 '26 |
Option Exercise |
9.59 |
58,292 |
559,020 |
2,410,772 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
Apr 01 '26 |
Sale |
203.31 |
8,400 |
1,707,814 |
224,885 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Apr 01 '26 |
Sale |
202.30 |
3,000 |
606,899 |
147,882 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Mar 31 '26 |
Option Exercise |
9.59 |
41,708 |
399,980 |
2,352,480 |
3.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):